Linagliptina Mylan

Linagliptin, the active ingredient in Linagliptina Mylan, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as a tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycemic control when used as part of a comprehensive treatment plan.

GNH USA supplies Linagliptina Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured medicines.

Linagliptin is used to treat disorders of glucose metabolism, primarily type 2 diabetes mellitus.

- Type 2 diabetes mellitus (monotherapy): reduces fasting and post‑prandial glucose levels as a single agent. - Type 2 diabetes mellitus (combination therapy): enhances glycemic control when added to metformin, sulfonylureas, or insulin. - Type 2 diabetes mellitus (adjunct to diet and exercise): supports overall blood glucose management as part of lifestyle interventions.

Common Side Effects: - Upper respiratory tract infection: mild symptoms such as cough or sore throat. - Nasopharyngitis: inflammation of the nasal passages and throat. - Headache: transient mild to moderate pain. - Gastrointestinal discomfort: occasional nausea or abdominal pain. - Skin rash: mild erythematous eruptions.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with vomiting, requiring immediate medical attention. - Severe hypersensitivity reactions: including angioedema or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Acute kidney injury: sudden decline in renal function, especially in patients with pre‑existing kidney disease.

Linagliptina Mylan should be used under medical supervision with regular monitoring of glycemic control.

- Renal impairment: dose adjustment is not required, but monitor kidney function regularly. - Hepatic disease: use with caution; assess liver enzymes periodically. - Cardiovascular risk: evaluate cardiovascular status, especially in patients with established disease. - Concomitant antidiabetic agents: adjust therapy to avoid hypoglycemia. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Linagliptina Mylan may interact with several drug classes; careful review of the patient's medication list is essential.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase linagliptin exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce linagliptin efficacy.

Moderate Interactions (Monitor Closely): - Insulin or insulin secretagogues (e.g., sulfonylureas): increased risk of hypoglycemia; adjust dose as needed. - Diuretics and antihypertensives: monitor blood pressure and electrolytes. - Anticoagulants (e.g., warfarin): periodic INR checks are advisable.